01390nas a2200469   4500000000100000000000100001000000100002008004100003653001100044653006500055653000900120653005500129653001100184653000900195653003200204653002600236653002100262653003900283653001700322653001600339653002100355653002200376653005500398653001700453653002300470653002200493653000900515653001800524653001800542653002900560653004100589100001400630700001500644700001200659700001300671700001600684245015500700250001500855300001100870490000700881020003200888       2024                            d10aHumans10a*Hyperuricemia/drug therapy/blood/epidemiology/complications10aMale10a*Heart Failure/epidemiology/drug therapy/mortality10aFemale10aAged10aUnited Kingdom/epidemiology10aRetrospective Studies10a*Uric Acid/blood10a*Gout Suppressants/therapeutic use10aRisk Factors10aMiddle Aged10aBiomarkers/blood10aTreatment Outcome10aGout/drug therapy/blood/complications/epidemiology10aTime Factors10aDatabases, Factual10aFollow-Up Studies10agout10aheart failure10ahyperuricemia10aurate‐lowering therapy10aanalysis and manuscript development.1 aS. Kiddle1 aK. Sundell1 aS. Perl1 aS. Nolan1 aM. Bjursell00aUrate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink  a2024/06/14  ae242970 v47  a0160-9289 (Print)
0160-9289